Hypertension (HTN)NCT07357272
A Cohort Study on Increasing Blood Pressure Benefits in Sleep Apnea Patients After CPAP Treatment
An observational study of Hypertension (HTN) and Sleep Apnea Syndrome, Obstructive, run by Beijing Anzhen Hospital at 1 site in China.
Trial summary
Research Title "Quadruple-Blind Randomized Controlled Trial of the Effect of CPAP on Blood Pressure in Patients with Sleep Apnea" Why are we conducting this study? Sleep apnea (OSA) is very common, affecting approximately one in every eight adults. It makes it more difficult to control blood pressure. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypertension (HTN), Sleep Apnea Syndrome, Obstructive
- What is being tested?
- continuous positive airway pressure
- Type of treatment
- Medical device
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- 15 Sep 2025to 1 Jul 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: People who meet the age and screening criteria
Who may be able to join
- Age between 18 and 70 years old;
- Diagnosed with obstructive sleep apnea (OSA) through overnight polysomnography (PSG), as follows: (1) AHI ≥ 5 times/hour and one of the following conditions is met: (1) The patient complains of daytime sleepiness, lack of sleepiness during sleep, fatigue or insomnia; (2) Waking up due to breathlessness or wheezing; (3) The bed partner or other witnesses report that the patient has habitual snoring, breathing interruptions or both during sleep. Or (2) AHI ≥ 15 times/hour.
- Satisfy any of the following blood pressure conditions: (1) Office blood pressure 120-139/80-89 mmHg, with ≤ 2 cardiovascular risk factors; (2) Newly diagnosed blood pressure 140-159/90-99 mmHg and without cardiovascular risk factors; (3) Currently taking stable types and doses of antihypertensive drugs, but the office blood pressure has not reached the normal blood pressure standard (120/80 mmHg) with a low-risk level of cardiovascular risk for patients with hypertension; (4) Any non-cardiovascular risk level high-risk patient who voluntarily requests three-month CPAP treatment and accepts follow-up;
- Able to tolerate 24-hour ambulatory blood pressure monitoring and continuous blood pressure monitoring;
Who cannot join
- Previously diagnosed with OSA and currently undergoing OSA treatment (such as CPAP, orthodontic devices, surgery, etc.);
- Secondary hypertension caused by other reasons other than OSA, such as renal artery stenosis, kidney disease, Cushing's syndrome, primary aldosteronism;
- Unstable condition (having experienced cardiovascular events or major surgeries in the past 3 months, severe sleepiness (ESS ≥ 16 points), or cognitive impairment that makes it impossible to cooperate, active mental illness or drug/alcohol abuse);
- Rheumatic immune diseases and malignant tumors;
- Large artery diseases (such as giant cell arteritis, arterial dissection, aneurysm, etc.);
- Diseases that cannot accurately measure blood pressure (such as atrial fibrillation, upper limb vascular diseases);
Show all 12Show fewer
- Early-onset familial hypertension;
- Any prescription or over-the-counter sleep aid (benzodiazepines, non-benzodiazepines, melatonin receptor agonists, trazodone, sedative antipsychotic/antidepressants containing sedative components, OTC containing sedative components) within 4 weeks before enrollment;
- Allergic or contraindicated to the potential study drugs (trazodone, zopiclone);
- Pregnant, lactating, or planning to become pregnant;
- Frequent night shift work (≥ 3 nights/week) or circadian rhythm disorder (diagnosed by a doctor);
- Participating in other interventional clinical trials.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100069
Jiang Xie, M.D., +86 010-64456527, Frank782008@aliyun.com
About this study
Research Title "Quadruple-Blind Randomized Controlled Trial of the Effect of CPAP on Blood Pressure in Patients with Sleep Apnea" Why are we conducting this study?
- Sleep apnea (OSA) is very common, affecting approximately one in every eight adults. It makes it more difficult to control blood pressure.
- Continuous Positive Airway Pressure (CPAP) is the preferred treatment, but the effect on blood pressure varies from person to person.
- We want to know: Which patients experience the greatest reduction in blood pressure with CPAP? Can adding a little sleep aid medication for those who have trouble sleeping or frequently wake up at night improve the effectiveness of CPAP and lead to better blood pressure control? Who will participate?
- 18-70 years old, diagnosed with obstructive sleep apnea, with snoring, gasping, or daytime sleepiness.
- High blood pressure or newly diagnosed with mild hypertension, or taking 1-2 blood pressure-lowering medications but not reaching the target.
- Able to wear the CPAP mask every night and willing to undergo 3-month follow-up.
- Pregnant women, those already using CPAP, those with a history of heart disease/stroke in the last 3 months, those working night shifts ≥ 3 nights/week, or those participating in other intervention trials are not eligible.
Read more
What will the study do? First, conduct a full-night sleep monitoring and 24-hour blood pressure monitoring to adjust the most suitable CPAP pressure for you.
Wear the CPAP mask for ≥ 4 hours every night, for a total of ≥ 21 days per month, for approximately 3 months.
If you often wake up at night or have insomnia, you can voluntarily join the "sleep aid medication" group: take trazodone (25-150 mg) or zolpidem (3.75-7.5 mg) before bedtime for 4 weeks.
During this period, we will use questionnaires, a small wristwatch (actigraphy), and additional sleep monitoring to observe changes in sleep and blood pressure; we will also draw a small amount of blood and collect urine for routine safety checks.
You can withdraw at any time without any penalty and it will not affect your regular medical treatment.
Possible benefits
- Free comprehensive assessment of sleep and blood pressure, one-on-one guidance from a doctor.
- May lead to a reduction in blood pressure and improvement in nighttime sleep quality.
- Help future patients like you receive better treatment. Possible discomfort or risks
- CPAP: mask pressure marks, dry mouth and nose, feeling of suffocation, bloating; most people's symptoms are relieved after adjusting the humidifier or mask.
- Sleep aid medication: next-day drowsiness, dry mouth, dizziness, nausea; rare cases may include persistent penile erection in men (immediate medical consultation required); the risk of dependency for zolpidem after continuous use for 4 weeks is very low, but it still requires monitoring by a doctor.
- Check: wearing a blood pressure cuff and sleep monitoring device may cause slight inconvenience during sleep.
- If there is any injury related to the study, Anzhen Hospital will provide necessary treatment and compensation in accordance with Chinese laws.
Privacy and Costs
- Sleep monitoring, dynamic blood pressure, medications, and tests required for the study are all free.
- Your name and medical record will only be viewed by researchers and the ethics committee. Personal identity will not be disclosed when the article is published. Contact person
- Research Question: Dr. Xie Jiang 010-64456528 (during working days) / 131-6198-5564 (at other times)
- Rights and Benefits: Beijing Anzhen Hospital Ethics Committee 010-64456214 Voluntary Decision Whether to participate or not is completely voluntary. You can withdraw at any time without any reason, and it will not affect the medical care you are entitled to.
- Being tested
- continuous positive airway pressure
- Medical subject headings
- Hypertension, Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
continuous positive airway pressureDevice
All will undergo auto-titrating CPAP for 3 months (≥4 h/night, ≥21 nights/month) with mask-fitting, education and side-effect management to maximize adherence.
| Study group | Role | What they receive |
|---|---|---|
| hypertension with OSA | We will enroll 200 adults 18-70 y with newly-diagnosed obstructive sleep apnea (AHI ≥5 + symptoms or ≥15/h) and untreated or sub-optimally controlled blood pressure (120-159/80-99 mmHg or on stable meds but not at target). All will undergo auto-titrating CPAP for 3 months (≥4 h/night, ≥21 nights/month) with mask-fitting, education and side-effect management to maximize adherence. Participants who report insomnia or frequent CPAP-related awakenings may additionally receive 4-week bedtime trazodone (25-150 mg) or zopiclone (3.75-7.5 mg) at physician discretion, creating natural sub-groups: CPAP-only, CPAP+trazodone, CPAP+zopiclone, or drug-only for those refusing CPAP. Outcomes: 24-h BP change, CPAP adherence, subjective/objective sleep quality. Exclusions: prior OSA therapy, secondary hypertension, unstable cardiopulmonary disease, pregnancy, rotating night shift, recent hypnotic use, or concurrent interventional trials. Receives: Device: continuous positive airway pressure |
What is being measured
The primary outcome is the main question the study is designed to answer.
blood pressure
The changes in blood pressure of the patient after receiving CPAP treatment
Measured: After 3 months of CPAP treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jan 2026
- Study start15 Sep 2025
- Primary completion1 Jul 2028 (estimated)
- Study completion1 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Hypertension (HTN)Studies of the same condition, open and under way.
- More trials run by Beijing Anzhen HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Anzhen Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07357272
- Sponsor's protocol ID
- KS2025179
- Status last verified
- Sep 2025
- First submitted
- 11 Sep 2025
- Last updated
- 21 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Currently, this trial is focused on completing the recruitment of participants and conducting the analysis of the primary endpoints. The final form and platform for data sharing have not yet been determined. Given that IPD sharing needs to take into account patient privacy protection, renewal of ethical approval, and negotiations regarding the intellectual property rights of the funding party, we reserve the right to formulate and upload a specific sharing plan (including de-identified data sets, analysis codes, and research protocols) within 6 months before the publication of the paper. Therefore, at this stage, we choose "Undecided". If we decide to share in the future, it will be freely accessible through OSF or a domestic compliant data repository in accordance with ICMJE requirements, and the registration record will be updated. If we ultimately do not share, the reasons will be clearly stated in this column.
Publications
Meng Z, Chen Y, Yang T, Sun B, Luo C, Wei G, Xie X, Gu Y, Ding N, Zhang X, Xu J. New perspective on exploring the predictive factors of blood pressure reduction during CPAP treatment in people with severe OSA and hypertension: a prospective observational study. BMJ Open Respir Res. 2023 May;10(1):e001560. doi: 10.1136/bmjresp-2022-001560.
PubMed 37169401Pengo MF, Oscullo G, Gomez-Olivas JD, Bilo G, Parati G, Martinez-Garcia MA. Nocturnal BP Profile Predicts CPAP Effect on BP in Patients With OSA and Resistant Hypertension. Chest. 2023 Nov;164(5):1302-1304. doi: 10.1016/j.chest.2023.05.021. Epub 2023 Jun 17. No abstract available.
PubMed 37364854Sanchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, Zapater A, Torres G, Sanchez-de-la-Torre A, Aldoma A, de Batlle J, Targa A, Abad J, Duran-Cantolla J, Urrutia A, Mediano O, Masdeu MJ, Ordax-Carbajo E, Masa JF, De la Pena M, Mayos M, Coloma R, Montserrat JM, Chiner E, Minguez O, Pascual L, Cortijo A, Martinez D, Dalmases M, Lee CH, McEvoy RD, Barbe F; Spanish Sleep Network. Long-Term Effect of Obstructive Sleep Apnea and Continuous Positive Airway Pressure Treatment on Blood Pressure in Patients with Acute Coronary Syndrome: A Clinical Trial. Ann Am Thorac Soc. 2022 Oct;19(10):1750-1759. doi: 10.1513/AnnalsATS.202203-260OC.
PubMed 35442180Labarca G, Schmidt A, Dreyse J, Jorquera J, Enos D, Torres G, Barbe F. Efficacy of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA) and resistant hypertension (RH): Systematic review and meta-analysis. Sleep Med Rev. 2021 Aug;58:101446. doi: 10.1016/j.smrv.2021.101446. Epub 2021 Jan 28.
PubMed 33607443Wu H, Guo Y. Risk of resistant hypertension associated with insomnia in patients with obstructive sleep apnea. Sleep Med. 2023 Jan;101:445-451. doi: 10.1016/j.sleep.2022.12.001. Epub 2022 Dec 5.
PubMed 36516601Shiina K. Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy. Hypertens Res. 2024 Nov;47(11):3085-3098. doi: 10.1038/s41440-024-01852-y. Epub 2024 Aug 29.
PubMed 39210083
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Cohort Study on Increasing Blood Pressure Benefits in Sleep Apnea Patients After CPAP Treatment
- ClinicalTrials.gov ID
- NCT07357272
- Acronym / sponsor ID
- KS2025179
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Beijing Anzhen HospitalUniversity, hospital or other
- Study start
- 15 Sep 2025 (actual)
- Primary completion
- 1 Jul 2028 (estimated)
- Study completion
- 1 Jul 2028 (estimated)
- First posted
- 21 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research Title "Quadruple-Blind Randomized Controlled Trial of the Effect of CPAP on Blood Pressure in Patients with Sleep Apnea" Why are we conducting this study?
- Sleep apnea (OSA) is very common, affecting approximately one in every eight adults. It makes it more difficult to control blood pressure.
- Continuous Positive Airway Pressure (CPAP) is the preferred treatment, but the effect on blood pressure varies from person to person.
- We want to know: Which patients experience the greatest reduction in blood pressure with CPAP? Can adding a little sleep aid medication for those who have trouble sleeping or frequently wake up at night improve the effectiveness of CPAP and lead to better blood pressure control? Who will participate?
- 18-70 years old, diagnosed with obstructive sleep apnea, with snoring, gasping, or daytime sleepiness.
- High blood pressure or newly diagnosed with mild hypertension, or taking 1-2 blood pressure-lowering medications but not reaching the target.
- Able to wear the CPAP mask every night and willing to undergo 3-month follow-up.
- Pregnant women, those already using CPAP, those with a history of heart disease/stroke in the last 3 months, those working night shifts ≥ 3 nights/week, or those participating in other intervention trials are not eligible.
What will the study do? First, conduct a full-night sleep monitoring and 24-hour blood pressure monitoring to adjust the most suitable CPAP pressure for you.
Wear the CPAP mask for ≥ 4 hours every night, for a total of ≥ 21 days per month, for approximately 3 months.
If you often wake up at night or have insomnia, you can voluntarily join the "sleep aid medication" group: take trazodone (25-150 mg) or zolpidem (3.75-7.5 mg) before bedtime for 4 weeks.
During this period, we will use questionnaires, a small wristwatch (actigraphy), and additional sleep monitoring to observe changes in sleep and blood pressure; we will also draw a small amount of blood and collect urine for routine safety checks.
You can withdraw at any time without any penalty and it will not affect your regular medical treatment.
Possible benefits
- Free comprehensive assessment of sleep and blood pressure, one-on-one guidance from a doctor.
- May lead to a reduction in blood pressure and improvement in nighttime sleep quality.
- Help future patients like you receive better treatment. Possible discomfort or risks
- CPAP: mask pressure marks, dry mouth and nose, feeling of suffocation, bloating; most people's symptoms are relieved after adjusting the humidifier or mask.
- Sleep aid medication: next-day drowsiness, dry mouth, dizziness, nausea; rare cases may include persistent penile erection in men (immediate medical consultation required); the risk of dependency for zolpidem after continuous use for 4 weeks is very low, but it still requires monitoring by a doctor.
- Check: wearing a blood pressure cuff and sleep monitoring device may cause slight inconvenience during sleep.
- If there is any injury related to the study, Anzhen Hospital will provide necessary treatment and compensation in accordance with Chinese laws.
Privacy and Costs
- Sleep monitoring, dynamic blood pressure, medications, and tests required for the study are all free.
- Your name and medical record will only be viewed by researchers and the ethics committee. Personal identity will not be disclosed when the article is published. Contact person
- Research Question: Dr. Xie Jiang 010-64456528 (during working days) / 131-6198-5564 (at other times)
- Rights and Benefits: Beijing Anzhen Hospital Ethics Committee 010-64456214 Voluntary Decision Whether to participate or not is completely voluntary. You can withdraw at any time without any reason, and it will not affect the medical care you are entitled to.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| hypertension with OSA | – | Device: continuous positive airway pressureWe will enroll 200 adults 18-70 y with newly-diagnosed obstructive sleep apnea (AHI ≥5 + symptoms or ≥15/h) and untreated or sub-optimally controlled blood pressure (120-159/80-99 mmHg or on stable meds but not at target). All will undergo auto-titrating CPAP for 3 months (≥4 h/night, ≥21 nights/month) with mask-fitting, education and side-effect management to maximize adherence. Participants who report insomnia or frequent CPAP-related awakenings may additionally receive 4-week bedtime trazodone (25-150 mg) or zopiclone (3.75-7.5 mg) at physician discretion, creating natural sub-groups: CPAP-only, CPAP+trazodone, CPAP+zopiclone, or drug-only for those refusing CPAP. Outcomes: 24-h BP change, CPAP adherence, subjective/objective sleep quality. Exclusions: prior OSA therapy, secondary hypertension, unstable cardiopulmonary disease, pregnancy, rotating night shift, recent hypnotic use, or concurrent interventional trials. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- People who meet the age and screening criteria
Key inclusion criteria (4 listed)
- Age between 18 and 70 years old;
- Diagnosed with obstructive sleep apnea (OSA) through overnight polysomnography (PSG), as follows: (1) AHI ≥ 5 times/hour and one of the following conditions is met: (1) The patient complains of daytime sleepiness, lack of sleepiness during sleep, fatigue or insomnia; (2) Waking up due to breathlessness or wheezing; (3) The bed partner or other witnesses report that the patient has habitual snoring, breathing interruptions or both during sleep. Or (2) AHI ≥ 15 times/hour.
- Satisfy any of the following blood pressure conditions: (1) Office blood pressure 120-139/80-89 mmHg, with ≤ 2 cardiovascular risk factors; (2) Newly diagnosed blood pressure 140-159/90-99 mmHg and without cardiovascular risk factors; (3) Currently taking stable types and doses of antihypertensive drugs, but the office blood pressure has not reached the normal blood pressure standard (120/80 mmHg) with a low-risk level of cardiovascular risk for patients with hypertension; (4) Any non-cardiovascular risk level high-risk patient who voluntarily requests three-month CPAP treatment and accepts follow-up;
- Able to tolerate 24-hour ambulatory blood pressure monitoring and continuous blood pressure monitoring;
Key exclusion criteria (12 listed)
- Previously diagnosed with OSA and currently undergoing OSA treatment (such as CPAP, orthodontic devices, surgery, etc.);
- Secondary hypertension caused by other reasons other than OSA, such as renal artery stenosis, kidney disease, Cushing's syndrome, primary aldosteronism;
- Unstable condition (having experienced cardiovascular events or major surgeries in the past 3 months, severe sleepiness (ESS ≥ 16 points), or cognitive impairment that makes it impossible to cooperate, active mental illness or drug/alcohol abuse);
- Rheumatic immune diseases and malignant tumors;
- Large artery diseases (such as giant cell arteritis, arterial dissection, aneurysm, etc.);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| continuous positive airway pressureAll will undergo auto-titrating CPAP for 3 months (≥4 h/night, ≥21 nights/month) with mask-fitting, education and side-effect management to maximize adherence. | Device | hypertension with OSA |
Primary outcome
blood pressure
Time frame: After 3 months of CPAP treatment
The changes in blood pressure of the patient after receiving CPAP treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Results publication: PubMed 37169401Meng Z, Chen Y, Yang T, Sun B, Luo C, Wei G, Xie X, Gu Y, Ding N, Zhang X, Xu J. New perspective on exploring the predictive factors of blood pressure reduction during CPAP treatment in people with severe OSA and hypertension: a prospective observational study. BMJ Open Respir Res. 2023 May;10(1):e001560. doi: 10.1136/bmjresp-2022-001560.
- Results publication: PubMed 37364854Pengo MF, Oscullo G, Gomez-Olivas JD, Bilo G, Parati G, Martinez-Garcia MA. Nocturnal BP Profile Predicts CPAP Effect on BP in Patients With OSA and Resistant Hypertension. Chest. 2023 Nov;164(5):1302-1304. doi: 10.1016/j.chest.2023.05.021. Epub 2023 Jun 17. No abstract available.
- Results publication: PubMed 35442180Sanchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, Zapater A, Torres G, Sanchez-de-la-Torre A, Aldoma A, de Batlle J, Targa A, Abad J, Duran-Cantolla J, Urrutia A, Mediano O, Masdeu MJ, Ordax-Carbajo E, Masa JF, De la Pena M, Mayos M, Coloma R, Montserrat JM, Chiner E, Minguez O, Pascual L, Cortijo A, Martinez D, Dalmases M, Lee CH, McEvoy RD, Barbe F; Spanish Sleep Network. Long-Term Effect of Obstructive Sleep Apnea and Continuous Positive Airway Pressure Treatment on Blood Pressure in Patients with Acute Coronary Syndrome: A Clinical Trial. Ann Am Thorac Soc. 2022 Oct;19(10):1750-1759. doi: 10.1513/AnnalsATS.202203-260OC.
- Results publication: PubMed 33607443Labarca G, Schmidt A, Dreyse J, Jorquera J, Enos D, Torres G, Barbe F. Efficacy of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA) and resistant hypertension (RH): Systematic review and meta-analysis. Sleep Med Rev. 2021 Aug;58:101446. doi: 10.1016/j.smrv.2021.101446. Epub 2021 Jan 28.
- Results publication: PubMed 36516601Wu H, Guo Y. Risk of resistant hypertension associated with insomnia in patients with obstructive sleep apnea. Sleep Med. 2023 Jan;101:445-451. doi: 10.1016/j.sleep.2022.12.001. Epub 2022 Dec 5.
- Results publication: PubMed 39210083Shiina K. Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy. Hypertens Res. 2024 Nov;47(11):3085-3098. doi: 10.1038/s41440-024-01852-y. Epub 2024 Aug 29.
- Individual participant dataSharing planned: Undecided. Currently, this trial is focused on completing the recruitment of participants and conducting the analysis of the primary endpoints. The final form and platform for data sharing have not yet been determined. Given that IPD sharing needs to take into account patient privacy protection, renewal of ethical approval, and negotiations regarding the intellectual property rights of the funding party, we reserve the right to formulate and upload a specific sharing plan (including de-identified data sets, analysis codes, and research protocols) within 6 months before the publication of the paper. Therefore, at this stage, we choose "Undecided". If we decide to share in the future, it will be freely accessible through OSF or a domestic compliant data repository in accordance with ICMJE requirements, and the registration record will be updated. If we ultimately do not share, the reasons will be clearly stated in this column.
Related trials for Hypertension (HTN)
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension (HTN) and Sleep Apnea Syndrome, Obstructive, run by Beijing Anzhen Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jiang Xie, M.D. (+86 010-64456527, Frank782008@aliyun.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
blood pressure (time frame: After 3 months of CPAP treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07357272, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.